EE200100666A - Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil - Google Patents

Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil

Info

Publication number: EE200100666A
Authority: EE; Estonia
Prior art keywords: protein aggregation; amyloid; inhibiting; isoindoline derivatives; imaging diagnostics
Prior art date: 1999-06-10

Application number

EEP200100666A

Other languages

English (en)

Estonian (et)

Inventor

Elizabeth Augelli-Szafran Corinne

Lai Yingjie

Theresa Sakkab Annette

Craswell Walker Lary

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-10

Filing date

2000-05-31

Publication date

2003-02-17

2000-05-31 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

2003-02-17 Publication of EE200100666A publication Critical patent/EE200100666A/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Optics & Photonics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Radiology & Medical Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EEP200100666A 1999-06-10 2000-05-31 Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil EE200100666A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13854399P	1999-06-10	1999-06-10
PCT/US2000/015073 WO2000076969A1 (fr)	1999-06-10	2000-05-31	Procede d'inhibition d'agregation de proteines amyloides et d'imagerie de depots amyloides au moyen de derives d'isoindoline

Publications (1)

Publication Number	Publication Date
EE200100666A true EE200100666A (et)	2003-02-17

Family

ID=22482508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100666A EE200100666A (et)	1999-06-10	2000-05-31	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil

Country Status (38)

Country	Link
EP (1)	EP1192131B1 (fr)
JP (1)	JP2003502313A (fr)
KR (1)	KR20020012266A (fr)
CN (1)	CN1156445C (fr)
AP (1)	AP1398A (fr)
AT (1)	ATE272623T1 (fr)
AU (1)	AU777747B2 (fr)
BG (1)	BG106291A (fr)
BR (1)	BR0011446A (fr)
CA (1)	CA2373394A1 (fr)
CR (1)	CR6530A (fr)
CZ (1)	CZ20014366A3 (fr)
DE (1)	DE60012742T2 (fr)
DK (1)	DK1192131T3 (fr)
DZ (1)	DZ3262A1 (fr)
EA (1)	EA004405B1 (fr)
EE (1)	EE200100666A (fr)
ES (1)	ES2223531T3 (fr)
GE (1)	GEP20043407B (fr)
HK (1)	HK1046283B (fr)
HR (1)	HRP20020027A2 (fr)
HU (1)	HUP0201586A2 (fr)
IL (1)	IL146455A0 (fr)
IS (1)	IS6162A (fr)
MA (1)	MA26807A1 (fr)
MX (1)	MXPA01011112A (fr)
NO (1)	NO20015992L (fr)
NZ (1)	NZ515619A (fr)
OA (1)	OA11958A (fr)
PL (1)	PL352294A1 (fr)
PT (1)	PT1192131E (fr)
SI (1)	SI1192131T1 (fr)
SK (1)	SK17622001A3 (fr)
TR (1)	TR200200257T2 (fr)
UA (1)	UA64842C2 (fr)
WO (1)	WO2000076969A1 (fr)
YU (1)	YU86801A (fr)
ZA (1)	ZA200109164B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6972287B1 (en)	1999-06-10	2005-12-06	Pfizer Inc.	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
SK17632001A3 (sk) *	1999-06-10	2003-03-04	Warner-Lambert Company	Liečivo na liečbu Alzheimerovej choroby, inhibíciu agregácie amyloidového proteínu a spôsob na zobrazenie depozít amyloidu
PE20020394A1 (es)	2000-08-18	2002-06-21	Agouron Pharma	Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (fr) *	2000-09-29	2002-03-29	Warner-Lambert Company	Analogues de phenoxazine pouvant etre utilises comme inhibiteurs d'agregation de substances amyloides et traitement de la maladie d'alzheimer et des troubles relatifs a l'amyloidose
GB0031302D0 (en) *	2000-12-21	2001-01-31	Glaxo Group Ltd	Napthalene derivatives
PE20040844A1 (es) *	2002-11-26	2004-12-30	Novartis Ag	Acidos fenilaceticos y derivados como inhibidores de la cox-2
GB2404855A (en) *	2003-07-07	2005-02-16	Pantherix Ltd	Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es)	2006-06-26	2008-09-10	Novartis Ag	Derivados de acido fenilacetico
KR101450356B1 (ko) *	2006-11-24	2014-10-15	에이씨 이뮨 에스.에이.	알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
CA2676715A1 (fr)	2007-02-12	2008-08-21	Merck & Co., Inc.	Derives de piperazine pour le traitement de la maladie d'alzheimer et des conditions apparentees
EP2687513B1 (fr) *	2008-06-09	2020-12-02	Ludwig-Maximilians-Universität München	Médicaments pour l'inhibition de l'agrégation des protéines impliquées dans des maladies associées à l'agrégation des protéines et/ou des maladies neurodégénératives
EA019685B1 (ru)	2009-02-06	2014-05-30	Янссен Фармасьютикалз, Инк.	Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh)	2009-02-19	2014-11-21	Janssen Pharmaceuticals Inc	作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
BRPI1011190A8 (pt) *	2009-05-07	2016-11-16	Janssen Pharmaceuticals Inc	Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase
ES2519565T3 (es)	2009-07-15	2014-11-07	Janssen Pharmaceuticals Inc.	Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa
EP2523949B1 (fr)	2010-01-15	2014-08-20	Janssen Pharmaceuticals Inc.	Nouveaux dérivés de triazole en tant que modulateurs de la secrétase gamma
CA2827969A1 (fr)	2011-03-24	2012-09-27	Janssen Pharmaceuticals, Inc.	Nouveaux derives de triazolylpiperazine et triazolylpiperidine substitues a titre de modulateurs de gamma secretases
TWI567079B (zh)	2011-07-15	2017-01-21	健生醫藥公司	作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
NZ702611A (en)	2012-05-16	2016-10-28	Cellzome Ltd	Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
AU2013366668B2 (en)	2012-12-20	2017-07-20	Janssen Pharmaceutica Nv	Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
ES2612215T3 (es)	2013-01-17	2017-05-12	Janssen Pharmaceutica, N.V.	Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa
US10562897B2 (en)	2014-01-16	2020-02-18	Janssen Pharmaceutica Nv	Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US10081629B2 (en) *	2014-04-14	2018-09-25	Jiangsu Hengrui Medicine Co., Ltd.	Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof
SI3186241T1 (sl) *	2014-08-29	2021-03-31	Chdi Foundation, Inc.	Sonde za slikanje Huntingtonovega proteina
TWI735416B (zh)	2014-10-06	2021-08-11	美商維泰克斯製藥公司	囊腫纖維化症跨膜傳導調節蛋白之調節劑
ES2946970T3 (es)	2016-03-31	2023-07-28	Vertex Pharma	Regulador de conductancia transmembrana de moduladores de fibrosis quística
SI3519401T1 (sl)	2016-09-30	2022-01-31	Vertex Pharmaceuticals Incorporated	Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
CN110267948B (zh)	2016-12-09	2023-12-08	弗特克斯药品有限公司	囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
CN110225753B (zh) *	2017-01-28	2022-12-09	金凯(辽宁)生命科技股份有限公司	用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
TWI799435B (zh)	2017-08-02	2023-04-21	美商維泰克斯製藥公司	製備化合物之製程
CN109232533A (zh) *	2017-09-28	2019-01-18	北京越之康泰生物医药科技有限公司	氮杂环类衍生物、其制备方法及其医药用途
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko)	2017-12-08	2024-10-14	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (fr)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
CA3226162A1 (fr)	2021-07-09	2023-01-12	Plexium, Inc.	Composes aryle et compositions pharmaceutiques modulant l'ikzf2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552426A (en) *	1994-04-29	1996-09-03	Eli Lilly And Company	Methods for treating a physiological disorder associated with β-amyloid peptide

2000
- 2000-05-31 YU YU86801A patent/YU86801A/sh unknown
- 2000-05-31 HU HU0201586A patent/HUP0201586A2/hu unknown
- 2000-05-31 ES ES00938023T patent/ES2223531T3/es not_active Expired - Lifetime
- 2000-05-31 IL IL14645500A patent/IL146455A0/xx unknown
- 2000-05-31 CZ CZ20014366A patent/CZ20014366A3/cs unknown
- 2000-05-31 DE DE2000612742 patent/DE60012742T2/de not_active Expired - Fee Related
- 2000-05-31 EP EP00938023A patent/EP1192131B1/fr not_active Expired - Lifetime
- 2000-05-31 TR TR2002/00257T patent/TR200200257T2/xx unknown
- 2000-05-31 EE EEP200100666A patent/EE200100666A/xx unknown
- 2000-05-31 DZ DZ003262A patent/DZ3262A1/fr active
- 2000-05-31 MX MXPA01011112A patent/MXPA01011112A/es not_active Application Discontinuation
- 2000-05-31 CN CNB008087288A patent/CN1156445C/zh not_active Expired - Fee Related
- 2000-05-31 AP APAP/P/2002/002389A patent/AP1398A/en active
- 2000-05-31 OA OA1200100320A patent/OA11958A/en unknown
- 2000-05-31 SI SI200030475T patent/SI1192131T1/xx unknown
- 2000-05-31 SK SK1762-2001A patent/SK17622001A3/sk unknown
- 2000-05-31 BR BR0011446-4A patent/BR0011446A/pt not_active IP Right Cessation
- 2000-05-31 NZ NZ515619A patent/NZ515619A/en unknown
- 2000-05-31 PL PL00352294A patent/PL352294A1/xx not_active Application Discontinuation
- 2000-05-31 WO PCT/US2000/015073 patent/WO2000076969A1/fr not_active Ceased
- 2000-05-31 CA CA002373394A patent/CA2373394A1/fr not_active Abandoned
- 2000-05-31 EA EA200101133A patent/EA004405B1/ru not_active IP Right Cessation
- 2000-05-31 AT AT00938023T patent/ATE272623T1/de not_active IP Right Cessation
- 2000-05-31 HK HK02107877.1A patent/HK1046283B/zh not_active IP Right Cessation
- 2000-05-31 PT PT00938023T patent/PT1192131E/pt unknown
- 2000-05-31 JP JP2001503829A patent/JP2003502313A/ja active Pending
- 2000-05-31 UA UA2001117664A patent/UA64842C2/uk unknown
- 2000-05-31 HR HR20020027A patent/HRP20020027A2/hr not_active Application Discontinuation
- 2000-05-31 KR KR1020017015827A patent/KR20020012266A/ko not_active Withdrawn
- 2000-05-31 DK DK00938023T patent/DK1192131T3/da active
- 2000-05-31 GE GE4625A patent/GEP20043407B/en unknown
- 2000-05-31 AU AU53120/00A patent/AU777747B2/en not_active Ceased
2001
- 2001-11-06 ZA ZA200109164A patent/ZA200109164B/en unknown
- 2001-11-15 IS IS6162A patent/IS6162A/is unknown
- 2001-12-07 NO NO20015992A patent/NO20015992L/no not_active Application Discontinuation
- 2001-12-07 CR CR6530A patent/CR6530A/es not_active Application Discontinuation
2002
- 2002-01-03 MA MA26467A patent/MA26807A1/fr unknown
- 2002-01-09 BG BG106291A patent/BG106291A/bg unknown

Also Published As

Publication number	Publication date
CN1156445C (zh)	2004-07-07
IS6162A (is)	2001-11-15
YU86801A (sh)	2004-07-15
ES2223531T3 (es)	2005-03-01
NO20015992L (no)	2002-02-06
NZ515619A (en)	2003-05-30
BR0011446A (pt)	2002-03-19
SK17622001A3 (sk)	2003-06-03
HRP20020027A2 (en)	2005-02-28
DE60012742D1 (de)	2004-09-09
EA004405B1 (ru)	2004-04-29
DE60012742T2 (de)	2005-01-13
BG106291A (bg)	2002-05-31
ZA200109164B (en)	2003-02-06
WO2000076969A1 (fr)	2000-12-21
HK1046283B (zh)	2005-01-07
HK1046283A1 (en)	2003-01-03
NO20015992D0 (no)	2001-12-07
GEP20043407B (en)	2004-05-10
UA64842C2 (uk)	2004-03-15
JP2003502313A (ja)	2003-01-21
CZ20014366A3 (cs)	2002-11-13
ATE272623T1 (de)	2004-08-15
IL146455A0 (en)	2002-07-25
MA26807A1 (fr)	2004-12-20
AP1398A (en)	2005-04-21
MXPA01011112A (es)	2002-06-04
AP2002002389A0 (en)	2002-03-31
CA2373394A1 (fr)	2000-12-21
EP1192131B1 (fr)	2004-08-04
PT1192131E (pt)	2004-11-30
SI1192131T1 (en)	2004-12-31
EP1192131A1 (fr)	2002-04-03
CR6530A (es)	2004-03-24
CN1355790A (zh)	2002-06-26
DZ3262A1 (fr)	2000-12-12
TR200200257T2 (tr)	2002-06-21
OA11958A (en)	2006-04-13
EA200101133A1 (ru)	2002-06-27
HUP0201586A2 (en)	2002-08-28
DK1192131T3 (da)	2004-12-13
KR20020012266A (ko)	2002-02-15
AU5312000A (en)	2001-01-02
AU777747B2 (en)	2004-10-28
PL352294A1 (en)	2003-08-11

Publication	Publication Date	Title
EE200100666A (et)	2003-02-17	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil
NO20003251D0 (no)	2000-06-22	Metode for magnetisk resonans avbildning
DE60217090D1 (de)	2007-02-08	Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
EP1171032A4 (fr)	2008-10-29	Procedes pour imagerie par resonance magnetique in vivo
EE200100673A (et)	2003-02-17	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks
EA200000274A3 (ru)	2003-02-27	Способы получения и промежуточные соединения для получения противораковых соединений
DE60029499D1 (de)	2006-09-07	Toner und Bildherstellungsverfahren
EE200200183A (et)	2003-06-16	Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
NO20023333D0 (no)	2002-07-10	Fremgangsmåte for bildefokusering og apparat for avbildning av borehullsresistivitet
FI970388A7 (fi)	1998-07-31	Menetelmä kuvasekvenssien kontrastin parantamiseksi
DE60030355D1 (de)	2006-10-12	Toner und Bildherstellungsverfahren
ATE275145T1 (de)	2004-09-15	Chinazolinderivate zur behandlung von tumoren
IT1302195B1 (it)	2000-07-31	Metodo e apparato per filtraggio di coerenza di immagini ultrasoniche.
DE60015555D1 (de)	2004-12-09	Abbildungsmethode mittels thermischem resonanz
NO20002517D0 (no)	2000-05-16	Magnetisk resonansavbildningsmidler for deteksjon av fysiologiske midler
EE04234B1 (et)	2004-02-16	L-fenüülefriinvesinikkloriidi valmistamise meetod
NO990523L (no)	1999-03-30	FremgangsmÕte for fremstilling av kontrastmidler for magnetresonanstomografi
NO20004561D0 (no)	2000-09-13	Metode for magnetisk resonansavbildning
DE69933911D1 (de)	2006-12-21	Phasenempfindliches Inversions-Rückstellungsverfahren der Magnetresonanzbildgebung
FI20021402L (fi)	2003-02-08	Menetelmä magneettiresonanssimittauksen kuvauksen homogenisoimiseksi
DE69710574D1 (de)	2002-03-28	Diclofenac/gamma-cyclodextrin klathrat komponente
TR200103562T2 (tr)	2002-04-22	Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
FI982704A0 (fi)	1998-12-14	Digitaalinen kuvantamismenetelmä ja laitteita digitaalisessa kuvantamisessa
FI991036A0 (fi)	1999-05-06	Tomosynteesimenetelmä ja laite tomosynteesikuvantamisessa
DE50012887D1 (de)	2006-07-20	MR-Verfahren zur Unterdrückung von MR-Signalen aus ausserhalb eines Isozentrums befindlichen Randbereichen